Barriers to predicting changes in global terrestrial methane fluxes: analyses using CLM4Me, a methane biogeochemistry model integrated in CESM

Terrestrial net CH<sub>4</sub> surface fluxes often represent the difference between much larger gross production and consumption fluxes and depend on multiple physical, biological, and chemical mechanisms that are poorly understood and represented in regional- and global-scale biogeochemical models. To characterize uncertainties, study feedbacks between CH<sub>4</sub> fluxes and climate, and to guide future model development and experimentation, we developed and tested a new CH<sub>4</sub> biogeochemistry model (CLM4Me) integrated in the land component (Community Land Model; CLM4) of the Community Earth System Model (CESM1). CLM4Me includes representations of CH<sub>4</sub> production, oxidation, aerenchyma transport, ebullition, aqueous and gaseous diffusion, and fractional inundation. As with most global models, CLM4 lacks important features for predicting current and future CH<sub>4</sub> fluxes, including: vertical representation of soil organic matter, accurate subgrid scale hydrology, realistic representation of inundated system vegetation, anaerobic decomposition, thermokarst dynamics, and aqueous chemistry. We compared the seasonality and magnitude of predicted CH<sub>4</sub> emissions to observations from 18 sites and three global atmospheric inversions. Simulated net CH<sub>4</sub> emissions using our baseline parameter set were 270, 160, 50, and 70 Tg CH<sub>4</sub> yr<sup>−1</sup> globally, in the tropics, in the temperate zone, and north of 45° N, respectively; these values are within the range of previous estimates. We then used the model to characterize the sensitivity of regional and global CH<sub>4</sub> emission estimates to uncertainties in model parameterizations. Of the parameters we tested, the temperature sensitivity of CH<sub>4</sub> production, oxidation parameters, and aerenchyma properties had the largest impacts on net CH<sub>4</sub> emissions, up to a factor of 4 and 10 at the regional and gridcell scales, respectively. In spite of these uncertainties, we were able to demonstrate that emissions from dissolved CH<sub>4</sub> in the transpiration stream are small (<1 Tg CH<sub>4</sub> yr<sup>−1</sup>) and that uncertainty in CH<sub>4</sub> emissions from anoxic microsite production is significant. In a 21st century scenario, we found that predicted declines in high-latitude inundation may limit increases in high-latitude CH<sub>4</sub> emissions. Due to the high level of remaining uncertainty, we outline observations and experiments that would facilitate improvement of regional and global CH<sub>4</sub> biogeochemical models

Sensitivity of wetland methane emissions to model assumptions: application and model testing against site observations

Peer reviewe

Present state of global wetland extent and wetland methane modelling: conclusions from a model inter-comparison project (WETCHIMP)

Global wetlands are believed to be climate sensitive, and are the largest natural emitters of methane (CH<sub>4</sub>). Increased wetland CH<sub>4</sub> emissions could act as a positive feedback to future warming. The Wetland and Wetland CH<sub>4</sub> Inter-comparison of Models Project (WETCHIMP) investigated our present ability to simulate large-scale wetland characteristics and corresponding CH<sub>4</sub> emissions. To ensure inter-comparability, we used a common experimental protocol driving all models with the same climate and carbon dioxide (CO<sub>2</sub>) forcing datasets. The WETCHIMP experiments were conducted for model equilibrium states as well as transient simulations covering the last century. Sensitivity experiments investigated model response to changes in selected forcing inputs (precipitation, temperature, and atmospheric CO<sub>2</sub> concentration). Ten models participated, covering the spectrum from simple to relatively complex, including models tailored either for regional or global simulations. The models also varied in methods to calculate wetland size and location, with some models simulating wetland area prognostically, while other models relied on remotely sensed inundation datasets, or an approach intermediate between the two. <br><br> Four major conclusions emerged from the project. First, the suite of models demonstrate extensive disagreement in their simulations of wetland areal extent and CH<sub>4</sub> emissions, in both space and time. Simple metrics of wetland area, such as the latitudinal gradient, show large variability, principally between models that use inundation dataset information and those that independently determine wetland area. Agreement between the models improves for zonally summed CH<sub>4</sub> emissions, but large variation between the models remains. For annual global CH<sub>4</sub> emissions, the models vary by ±40% of the all-model mean (190 Tg CH<sub>4</sub> yr<sup>−1</sup>). Second, all models show a strong positive response to increased atmospheric CO<sub>2</sub> concentrations (857 ppm) in both CH<sub>4</sub> emissions and wetland area. In response to increasing global temperatures (+3.4 °C globally spatially uniform), on average, the models decreased wetland area and CH<sub>4</sub> fluxes, primarily in the tropics, but the magnitude and sign of the response varied greatly. Models were least sensitive to increased global precipitation (+3.9 % globally spatially uniform) with a consistent small positive response in CH<sub>4</sub> fluxes and wetland area. Results from the 20th century transient simulation show that interactions between climate forcings could have strong non-linear effects. Third, we presently do not have sufficient wetland methane observation datasets adequate to evaluate model fluxes at a spatial scale comparable to model grid cells (commonly 0.5°). This limitation severely restricts our ability to model global wetland CH<sub>4</sub> emissions with confidence. Our simulated wetland extents are also difficult to evaluate due to extensive disagreements between wetland mapping and remotely sensed inundation datasets. Fourth, the large range in predicted CH<sub>4</sub> emission rates leads to the conclusion that there is both substantial parameter and structural uncertainty in large-scale CH<sub>4</sub> emission models, even after uncertainties in wetland areas are accounted for

The performance of FLake in the Met Office Unified Model

We present results from the coupling of FLake to the Met Office Unified Model (MetUM). The coupling and initialisation are first described, and the results of testing the coupled model in local and global model configurations are presented. These show that FLake has a small statistical impact on screen temperature, but has the potential to modify the weather in the vicinity of areas of significant inland water. Examination of FLake lake ice has revealed that the behaviour of lakes in the coupled model is unrealistic in some areas of significant sub-grid orography. Tests of various modifications to ameliorate this behaviour are presented. The results indicate which of the possible model changes best improve the annual cycle of lake ice. As FLake has been developed and tuned entirely outside the Unified Model system, these results can be interpreted as a useful objective measure of the performance of the Unified Model in terms of its near-surface characteristics

WETCHIMP-WSL: Intercomparison of wetland methane emissions models over West Siberia

© 2015 Author(s). Wetlands are the world's largest natural source of methane, a powerful greenhouse gas. The strong sensitivity of methane emissions to environmental factors such as soil temperature and moisture has led to concerns about potential positive feedbacks to climate change. This risk is particularly relevant at high latitudes, which have experienced pronounced warming and where thawing permafrost could potentially liberate large amounts of labile carbon over the next 100 years. However, global models disagree as to the magnitude and spatial distribution of emissions, due to uncertainties in wetland area and emissions per unit area and a scarcity of in situ observations. Recent intensive field campaigns across the West Siberian Lowland (WSL) make this an ideal region over which to assess the performance of large-scale process-based wetland models in a high-latitude environment. Here we present the results of a follow-up to the Wetland and Wetland CH4 Intercomparison of Models Project (WETCHIMP), focused on the West Siberian Lowland (WETCHIMP-WSL). We assessed 21 models and 5 inversions over this domain in terms of total CH4 emissions, simulated wetland areas, and CH4 fluxes per unit wetland area and compared these results to an intensive in situ CH4 flux data set, several wetland maps, and two satellite surface water products. We found that (a) despite the large scatter of individual estimates, 12-year mean estimates of annual total emissions over the WSL from forward models (5.34 ± 0.54 Tg CH4 yrg'1), inversions (6.06 ± 1.22 Tg CH4 yrg'1), and in situ observations (3.91 ± 1.29 Tg CH4 yrg'1) largely agreed; (b) forward models using surface water products alone to estimate wetland areas suffered from severe biases in CH4 emissions; (c) the interannual time series of models that lacked either soil thermal physics appropriate to the high latitudes or realistic emissions from unsaturated peatlands tended to be dominated by a single environmental driver (inundation or air temperature), unlike those of inversions and more sophisticated forward models; (d) differences in biogeochemical schemes across models had relatively smaller influence over performance; and (e) multiyear or multidecade observational records are crucial for evaluating models' responses to long-term climate change

Simulation of surface energy fluxes and stratification of a small boreal lake by a set of one-dimensional models

Peer reviewe

Wegner Estimate and Disorder Dependence for Alloy-Type Hamiltonians with Bounded Magnetic Potential

We consider non-ergodic magnetic random Sch\"odinger operators with a bounded magnetic vector potential. We prove an optimal Wegner estimate valid at all energies. The proof is an adaptation of the arguments from [Kle13], combined with a recent quantitative unique continuation estimate for eigenfunctions of elliptic operators from [BTV15]. This generalizes Klein's result to operators with a bounded magnetic vector potential. Moreover, we study the dependence of the Wegner-constant on the disorder parameter. In particular, we show that above the model-dependent threshold $E_0(\infty) \in (0, \infty]$, it is impossible that the Wegner-constant tends to zero if the disorder increases. This result is new even for the standard (ergodic) Anderson Hamiltonian with vanishing magnetic field

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Background The antiviral drug molnupiravir was licensed for treating at-risk patients with COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety and virological efficacy of molnupiravir in vaccinated and unvaccinated individuals with COVID-19. Methods This randomised, placebo-controlled, double-blind, phase 2 trial (AGILE CST-2) was done at five National Institute for Health and Care Research sites in the UK. Eligible participants were adult (aged ≥18 years) outpatients with PCR-confirmed, mild-to-moderate SARS-CoV-2 infection who were within 5 days of symptom onset. Using permuted blocks (block size 2 or 4) and stratifying by site, participants were randomly assigned (1:1) to receive either molnupiravir (orally; 800 mg twice daily for 5 days) plus standard of care or matching placebo plus standard of care. The primary outcome was the time from randomisation to SARS-CoV-2 PCR negativity on nasopharyngeal swabs and was analysed by use of a Bayesian Cox proportional hazards model for estimating the probability of a superior virological response (hazard ratio [HR]>1) for molnupiravir versus placebo. Our primary model used a two-point prior based on equal prior probabilities (50%) that the HR was 1·0 or 1·5. We defined a priori that if the probability of a HR of more than 1 was more than 80% molnupiravir would be recommended for further testing. The primary outcome was analysed in the intention-to-treat population and safety was analysed in the safety population, comprising participants who had received at least one dose of allocated treatment. This trial is registered in ClinicalTrials.gov, NCT04746183, and the ISRCTN registry, ISRCTN27106947, and is ongoing. Findings Between Nov 18, 2020, and March 16, 2022, 1723 patients were assessed for eligibility, of whom 180 were randomly assigned to receive either molnupiravir (n=90) or placebo (n=90) and were included in the intention-to-treat analysis. 103 (57%) of 180 participants were female and 77 (43%) were male and 90 (50%) participants had received at least one dose of a COVID-19 vaccine. SARS-CoV-2 infections with the delta (B.1.617.2; 72 [40%] of 180), alpha (B.1.1.7; 37 [21%]), omicron (B.1.1.529; 38 [21%]), and EU1 (B.1.177; 28 [16%]) variants were represented. All 180 participants received at least one dose of treatment and four participants discontinued the study (one in the molnupiravir group and three in the placebo group). Participants in the molnupiravir group had a faster median time from randomisation to negative PCR (8 days [95% CI 8–9]) than participants in the placebo group (11 days [10–11]; HR 1·30, 95% credible interval 0·92–1·71; log-rank p=0·074). The probability of molnupiravir being superior to placebo (HR>1) was 75·4%, which was less than our threshold of 80%. 73 (81%) of 90 participants in the molnupiravir group and 68 (76%) of 90 participants in the placebo group had at least one adverse event by day 29. One participant in the molnupiravir group and three participants in the placebo group had an adverse event of a Common Terminology Criteria for Adverse Events grade 3 or higher severity. No participants died (due to any cause) during the trial. Interpretation We found molnupiravir to be well tolerated and, although our predefined threshold was not reached, we observed some evidence that molnupiravir has antiviral activity in vaccinated and unvaccinated individuals infected with a broad range of SARS-CoV-2 variants, although this evidence is not conclusive